Becton Dickinson (BDX) Reports In-Line Q4 EPS; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Becton Dickinson (BDX) slumps after guidance disappoints investors
November 9, 2023 12:02 PM ESTShares of medical device maker Becton Dickinson (NYSE: BDX) declined Thursday after it reported quarterly results, along with guidance for 2024. Its outlook was viewed was well below Wall Street expectations and a disappointment to investors.
Becton Dickinson reported earnings per share for its fourth quarter that were in-line with consensus at $3.42. Revenue was slightly better than expected, coming in at $5.1 billion, compared to the consensus of $5.02... More
